Baltimore, Maryland -- Medical device technology company eNeura has secured $560,000 in a new investment financing.
eNeura says that it is "pioneering the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for treatment of migraine" headaches.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of 70 investors participated in the offering as amended.
eNeura is still seeking $24.7 million in additional equity investment, according to the filing.
Minimum investment size per investor was listed as $10,000.
CEO David Rosen has been with the firm since 2012, and was previously president and CEO of Aratana Therapeutics.